New drug close to US approval

The United States Food and Drug Administration (FDA, for its acronym in English) is studying the approval of a promising drug for fight obesity. It is about tirzepatide, a medicine to treat type 2 diabetes of the Eli Lilly Laboratory.

This pharmacist would have already delivered all the necessary documentation to the regulatory agency and it is expected that this same year is available for patients, as reported by Infobae. As clinical trials have shown, the drug is effective for weight loss, as it is a GLP-1 agonist medicationwhich mimics a hormone that helps reduce food intake and appetite.

The main difference from tirzepatide is that it also mimics a second hormone, the GIP, whose function is to improve the breakdown of sugars and fats. In fact, according to the results of the phase three study carried out by researchers from the New York-Presbyterian/Weill Cornell Medical Center and published in The New England Journal of Medicine show a 21 percent weight reduction in patients with obesity. Specifically, they participated 2,5000 volunteers in this analysis.

Another positive aspect of this treatment is that it is not chronic. Namely, can be administered for one year to lose weight and then remove it.

‘A before and after’ in the treatment of obesity

In Spain, specialists already celebrated these months ago positive results and hope they can manage this obesity treatment in the shortest possible time. In addition, coordination between family doctors and endocrinologists will be crucial for its use. From the Spanish Society of Endocrinology and Nutrition (SEEN) they affirm that the relationship between both specialists in the treatment of this pathology must always occur “with the corresponding referral criteria established between the two specialties”.

They also state that tirzepatide as a pharmacological treatment for obesity marks “one before and one after in the management of people with excess weight”. Currently, this product is available in Spain for treat type 2 diabetes.

Regarding your financing, you will first have to authorized by the National Health System (SNS) and may be prescribed by Primary Care physicians and other specialists. However, it may be that the Ministry of Health do not take charge of its cost.

Although it may contain statements, data or notes from health institutions or professionals, the information contained in Redacción Médica is edited and prepared by journalists. We recommend to the reader that any health-related questions be consulted with a health professional.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button